Newsfeeds - Spark Newswire

5 minute read

The Daily Biotech Pulse: Lilly Spikes On Alzheimer’s Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO

Today, 2:31 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23)

ABCL

6 minute read

14 Biotech Stocks To Watch Over The Next 6 Months

By Shanthi Rexaline

Today, 2:31 PM

Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks.

AERI

5 minute read

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs

By Shanthi Rexaline

Today, 2:31 PM

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.

ABBV

10 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For June 18, 2021

By Benzinga Insights

Today, 2:31 PM

ABMD

2 minute read

Senator Joe Manchin Urges President Biden Not To Nominate Janet Woodcock As FDA Commissioner

By Vandana Singh

Today, 2:31 PM

While Senator Joe Manchin has been vocal on his opposition to Janet Woodcock as Biden’s choice for FDA…

BIIB

1 minute read

10 Biggest Price Target Changes For Friday

By Lisa Levin

Today, 2:31 PM

Piper Sandler raised Adobe Inc. (NASDAQ: ADBE) price target from $570 to $600. Adobe shares rose 3.3% to $569.50 in pre-market trading.

ADBE

1 minute read

Piper Sandler Upgrades Biogen to Overweight, Raises Price Target to $450

By Benzinga Newsdesk

Today, 2:31 PM

Piper Sandler analyst Christopher Raymond upgrades Biogen (NASDAQ:BIIB) from Neutral to Overweight and raises the price target from $384 to $450.

BIIB

1 minute read

Biogen Commences Dosing In Late-Stage Systemic Lupus Erythematosus Study With BIIB059

By Vandana Singh

Today, 2:31 PM

Biogen Inc (NASDAQ:BIIB) has dosed the first patient in the TOPAZ-1 Phase 3 study evaluating BIIB059 in participants with active systemic…

BIIB

2 minute read

News

Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study

By Benzinga Newsdesk

Today, 2:31 PM

Biogen Inc. (NASDAQ:BIIB) today announced that the first patient has been dosed in the global clinical study, TOPAZ-1. The Phase 3 study will evaluate the clinical efficacy and assess the safety of BIIB059, a first

BIIB

1 minute read

Biogen Discontinues Tau Antibody Program For Alzheimer’s After Mid-Stage Study Flops

By Vandana Singh

Today, 2:31 PM

Biogen Inc (NASDAQ: BIIB) has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, of which one has just been canned.

BIIB